Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from…
By A. Rinke, H. Müller, C. Schade-Brittinger, K. Klose, P. Barth, M. Wied, C. Mayer, B. Aminossadati, U. Pape, M. Bläker and 4 more. Journal of Clinical Oncology, 2009
1,832 citations recorded by the source corpus.
Subfields: Endocrinology, Diabetes and Metabolism, Epidemiology, Oncology
View Paper: https://www.semanticscholar.org/paper/a2dfa8b60cf3a477ecabe1ddbe435657d9831281
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
- J. Zaknun
- L. Bodei
- J. Ramage
- J. Mueller‐Brand
- R. Thakker
- R. Baum
- A. Ahmed
- Dieter Hörsch
Citations in the corpus
- Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. (2011, neutral): “Mucosal inflammation 13 (16) 12 (14) 1 (1) 6 (7) 6 (7) 0”
- Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors (2017, neutral): “Midgut, not otherwise specified 9 (8) 7 (6)”
- Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours (NETs) (2005, result): “In this study, the best results were demonstrated in patients with low hepatic tumour load and a resected primary lesion.(285) Finally, there is an ongoing study assessing the antiproliferative effects of lanreotide Autogel in patients with nonfunctioning intestinal and pancreatic NETs.”
- The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours (2013, background): “The NCCN guidelines and very recently the ENETS guidelines have added octreotide as an option for antiproliferative treatment [23, 24].”
- Pulmonary neuroendocrine (carcinoid) tumors: European Neuroendocrine Tumor Society expert consensus and recommendations for best practice for typical and atypical pulmonary carcinoids. (2015, neutral): “3 months versus 6 months, respectively [148].”
- Gastroenteropancreatic neuroendocrine neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2020, neutral): “SSAs can be recommended in patients with unknown disease status, stable or Lu, lutetium-177; IFN-a , interferon alpha; LAR, long-acting release; NET, neuroendocrine tumour; PRRT, peptide receptor radionuclide therapy; RFA, radiofrequency ablation; s.c., subcutaneous; SIRT, selective internal radioth”
- Lanreotide in metastatic enteropancreatic neuroendocrine tumors. (2014, neutral): “Finally, our study included only patients with nonfunctioning tumors, whereas PROMID did include some patients with mildly functioning tumors and showed similar treatment effects on time to tumor progression in patients with nonfunctioning tumors.(11)”